Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey,
Ph.D., the company's president and chief executive officer, will present
at the J.P. Morgan 31st Annual Healthcare Conference at 5:00
p.m. EST / 2:00 p.m. PST on Wednesday, January 9, 2013, in San
Francisco. During the presentation, Dr. Morrissey will review the
company's development plans and priorities for cabozantinib in 2013. He
will also discuss the company's corporate strategy and financial
outlook, and provide a general business update.
The presentation will be webcast an may be accessed via the Event
Calendar page under Investors & Media at www.exelixis.com.
Exelixis, Inc. is a biotechnology company committed to developing small
molecule therapies for the treatment of cancer. Exelixis is focusing its
proprietary resources and development efforts exclusively on COMETRIQ™
(cabozantinib). Exelixis has also established a portfolio of other novel
compounds that it believes have the potential to address serious unmet
medical needs, many of which are being advanced by partners as part of
collaborations. For more information, please visit the company's web
site at www.exelixis.com.
[ Back To NFVZone's Homepage ]